India Releases 7th Edition of National Formulary of India, Strengthens Focus on Safer and Rational Medicine Use
India has released the 7th Edition of the National Formulary of India (NFI), reinforcing the country’s focus on the rational, safe and evidence-based use of medicines across the healthcare system.
The latest edition was released in New Delhi by Anupriya Patel, Union Minister of State for Health and Family Welfare and Chemicals & Fertilisers, as part of efforts to strengthen India’s medicine-safety and pharmacovigilance ecosystem.
Strengthening Rational Use of Medicines
The National Formulary of India serves as a reference resource intended to support healthcare professionals in making informed decisions about medicines and promoting their rational use. The Indian Pharmacopoeia Commission (IPC), an autonomous organisation under the Ministry of Health and Family Welfare, is responsible for publications including the NFI and the Indian Pharmacopoeia.
The release comes at a time when India is placing greater emphasis on medication safety, adverse drug reaction monitoring and appropriate prescribing practices.
The IPC is currently observing the 6th National Pharmacovigilance Week from September 17 to 23, 2026, under the theme “Promoting Rational Use of Medicines through Pharmacovigilance – A Step Towards Safer Healthcare.” The campaign aims to increase awareness among healthcare professionals, researchers and the public about adverse drug reaction (ADR) reporting.
More Than 1,100 ADR Monitoring Centres
According to statements reported during the NFI release, India currently has more than 1,100 Adverse Drug Reaction Monitoring Centres operating across the country. The government has indicated an objective of expanding pharmacovigilance capacity further toward primary healthcare facilities.
These centres form part of India’s Pharmacovigilance Programme of India (PvPI), which monitors suspected adverse reactions associated with medicines and helps generate safety information for healthcare decision-making.
The IPC serves as the National Coordination Centre for PvPI. Government guidance states that the programme was established to help ensure that the benefits of medicines outweigh their associated risks.
India Expands Participation in Global Medicine-Safety Monitoring
India is also contributing pharmacovigilance information to the World Health Organization’s global patient-safety database. According to the minister’s remarks reported by Akashvani, India’s contribution ranking has risen substantially over the past decade.
The development reflects the growing importance of national adverse-event reporting systems in identifying potential medicine-safety signals and supporting regulatory and clinical action.
The IPC has also highlighted the need for stronger pharmacovigilance networks at the grassroots level. During National Pharmacovigilance Week, the commission said it aspires to have at least one ADR Monitoring Centre and one Medical Device Monitoring Centre in every Aspirational District.
Focus on Preventing Medication-Related Risks
The NFI release is part of a wider push to encourage healthcare professionals and patients to use medicines responsibly.
The IPC‘s current pharmacovigilance campaign is encouraging doctors, pharmacists, nurses, healthcare institutions and members of the public to report suspected adverse drug reactions. Such reports can help authorities identify recurring safety patterns and investigate potential risks associated with medicines.
The government has also been working to strengthen pharmacovigilance through partnerships involving medicine-distribution networks. In April 2026, the IPC signed an MoU with the Pharmaceuticals & Medical Devices Bureau of India to strengthen quality assurance and promote rational medicine use through Jan Aushadhi Kendras, including measures to encourage ADR reporting.
Implications for India’s Healthcare System
The updated NFI could serve as an important reference for healthcare professionals as India’s pharmaceutical and healthcare sectors continue to expand.
For patients, stronger pharmacovigilance can provide an additional layer of protection by helping regulators identify previously unrecognised or emerging medicine-safety concerns.
For doctors and pharmacists, greater availability and use of standardised medicine information can support more consistent prescribing and dispensing practices.
For India’s pharmaceutical industry, stronger safety monitoring also contributes to the development of a more mature regulatory environment and can support confidence in Indian medicines domestically and internationally.
A Broader Push for Patient Safety
The release of the 7th NFI comes alongside several initiatives by the Indian Pharmacopoeia Commission focused on medicine quality and patient safety. The commission is also responsible for maintaining the Indian Pharmacopoeia, India’s official standards for medicines, while coordinating national programmes for monitoring medicines and medical devices.
As India expands access to medicines and strengthens its healthcare infrastructure, the combination of rational prescribing, quality standards, pharmacovigilance and adverse-event reporting is becoming increasingly important.
The 7th Edition of the National Formulary of India therefore represents not only an updated reference for medicines, but also part of a broader effort to promote safer medication practices and stronger patient protection across India’s healthcare ecosystem.
